sulfasalazine has been researched along with Cardiovascular Diseases in 7 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib was neutral regarding CVD risk in AS patients." | 5.46 | Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017) |
| "Celecoxib was neutral regarding CVD risk in AS patients." | 1.46 | Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017) |
| "Our study showed that treatment of early rheumatoid arthritis with a combination regime of traditional DMARDs is highly effective in controlling disease activity as well as cardiovascular risk." | 1.39 | Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs. ( Biswas, M; Chatterjee, S; Ghosh, A; Ghosh, S; Sarkate, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Mikkelsen, RR | 1 |
| Hundahl, MP | 1 |
| Torp, CK | 1 |
| Rodríguez-Carrio, J | 1 |
| Kjolby, M | 1 |
| Bruun, JM | 1 |
| Kragstrup, TW | 1 |
| Pers, YM | 1 |
| Padern, G | 1 |
| Chatterjee, S | 1 |
| Sarkate, P | 1 |
| Ghosh, S | 1 |
| Biswas, M | 1 |
| Ghosh, A | 1 |
| Tam, HW | 1 |
| Yeo, KJ | 1 |
| Leong, PY | 1 |
| Chen, CH | 1 |
| Li, YC | 1 |
| Ma, CM | 1 |
| Wang, YH | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Başkan, BM | 1 |
| Sivas, F | 1 |
| Aktekin, LA | 1 |
| Doğan, YP | 1 |
| Ozoran, K | 1 |
| Bodur, H | 1 |
| Cleland, LG | 1 |
| Caughey, GE | 1 |
| James, MJ | 1 |
| Proudman, SM | 1 |
| van Halm, VP | 1 |
| Nurmohamed, MT | 1 |
| Twisk, JW | 1 |
| Dijkmans, BA | 1 |
| Voskuyl, AE | 1 |
1 review available for sulfasalazine and Cardiovascular Diseases
| Article | Year |
|---|---|
Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Colchicine; Diabetes Mellitus, | 2022 |
1 trial available for sulfasalazine and Cardiovascular Diseases
| Article | Year |
|---|---|
Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arachidonic Acid; Arthritis, Rheumatoid; Cardiovascular Diseases; | 2006 |
5 other studies available for sulfasalazine and Cardiovascular Diseases
| Article | Year |
|---|---|
Revisiting the cardiovascular risk of hydroxychloroquine in RA.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Arthritis, Rheumatoid; Azithromycin; Ca | 2020 |
Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovasc | 2013 |
Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib | 2017 |
Serum homocysteine level in patients with ankylosing spondylitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Biomarkers; Blood Sedimentatio | 2009 |
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Case-Control Studies; Fe | 2006 |